The Dec. 27, 2024, Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors opened up ...
Most recently, the Food and Drug Administration (FDA) approved treatment with the subcutaneous injection formulation of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for patients with solid tumors ...
In extending patent protection for its primary cancer medication, Keytruda, Merck (NYSE:MRK) intends to introduce a subcutaneous form of it this year. It's important to also note that Merck is ...
Several key secondary end points of the trial, like very good partial response, incidence rate of infusion reactions, and C trough at cycle 2, were also met with subcutaneous isatuximab. “The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback